The human prion protein residue 129 polymorphism lies within a cluster of epitopes for T cell recognition

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 11, 2006, Pages 1059-1068

  Isaacs, Jeremy D ^a,b   Ingram, Rebecca J ^a   Collinge, John ^b   Altmann, Daniel M ^a   Jackson, Graham S ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Creutzfeldt Jakob disease; Prion protein; T cell responses

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 6; PRION PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CYTOKINE RELEASE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOLECULAR RECOGNITION; NONHUMAN; PREDICTION; PRION DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE;

ALGORITHMS; CYTOKINES; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; LEUKOCYTES, MONONUCLEAR; POLYMORPHISM, GENETIC; PRIONS;

EID: 33750599513     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000240467.18381.49     Document Type: Article

References (60)

1. Collinge J. Prion diseases of humans and animals: Their causes and molecular basis. Annu Rev Neurosci 2001;24:519-50
2. Griffith JS. Self-replication and scrapie. Nature 1967;215:1043-44
3. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136-44
4. Aucouturier P, Carnaud C. The immune system and prion diseases: A relationship of complicity and blindness. J Leukoc Biol 2002;72:1075-83
5. Stahl N, Borchelt DR, Hsiao K, et al. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987;51:229-40
6. Lasmezas CI. Putative functions of PrP(C). Br Med Bull 2003;66:61-70
7. Stahl N, Baldwin MA, Teplow DB, et al. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 1993;32:1991-2002
8. Jackson GS, Beck JA, Navarrete C, et al. HLA-DQ7 antigen and resistance to variant CJD. Nature 2001;414:269-70
9. Pepys MB, Bybee A, Booth DR, et al. MHC typing in variant Creutzfeldt-Jakob disease. Lancet 2003;361:487-89
10. Hill AF, Joiner S, Linehan J, et al. Species barrier independent prion replication in apparently resistant species. Proc Natl Acad Sci U S A 2000;97:10248-53
11. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-21
12. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527-29
13. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-77
14. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-54
15. Schwarz A, Kratke O, Burwinkel M, et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 2003;350:187-89
16. Goni F, Knudsen E, Schreiber F, et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005;133:413-21
17. Magri G, Clerici M, Dall'Ara P, et al. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine 2005;23:2862-68
18. Sigurdsson EM, Brown DR, Daniels M, et al. Immunization delays the onset of prion disease in mice. Am J Pathol 2002;161:13-17
19. Bade S, Baier M, Boetel T, et al. Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathy. Vaccine 2006;24:1242-53
20. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. Neurology 2003;61:46-54
21. Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 2003;9:448-52
22. Legname G, Baskakov IV, Nguyen HO, et al. Synthetic mammalian prions. Science 2004;305:673-76
23. Bainbridge J, Walker B. Cell mediated immune responses against human prion protein. Clin Exp Immunol 2003;133:310-17
24. Gregoire S, Logre C, Metharom P, et al. Identification of two immunogenic domains of the prion protein - PrP - which activate class II-restricted T cells and elicit antibody responses against the native molecule. J Leukoc Biol 2004;76:125-34
25. Khalili-Shirazi A, Quaratino S, Londei M, et al. Protein conformation significantly influences immune responses to prion protein. J Immunol 2005;174:3256-63
26. Stoltze L, Rezaei H, Jung G, et al. CD4+ T cell-mediated immunity against prion proteins. Cell Mol Life Sci 2003;60:629-38
27. Rosset MB, Ballerini C, Gregoire S, et al. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 2004;172:5168-74
28. Souan L, Tal Y, Felling Y, et al. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur J Immunol 2001;31:2338-46
29. Bian HJ, Reidhaar-Olson JF, Hammer J. The use of bioinformatics for identifying class II-restricted T-cell epitopes. Methods 2003;29:299-309
30. Bian HJ, Hammer J. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 2004;34:468-75
31. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995;46:355-67
32. Bunce M, Procter J, Welsh KI. A DNA-based detection and screening system for identifying HLA class I expression variants by sequence-specific primers. Tissue Antigens 1999;53:498-506
33. Wadsworth JDF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-blotting assay. Lancet 2001;358:171-80
34. Joiner S, Linehan JM, Brandner S, et al. High levels of disease related prion protein in the ileum in variant Creutzfeldt-Jakob disease. Gut 2005;54:1506-08
35. Glatzel M, Abela E, Maissen M, et al. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003;349:1812-20
36. Cunningham C, Wilcockson DC, Boche D, et al. Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease. J Virol 2005;79:5174-84
37. Lewicki H, Tishon A, Homann D, et al. T cells infiltrate the brain in murine and human transmissible spongiform encephalopathies. J Virol 2003;77:3799-808
38. Perry VH, Cunningham C, Boche D. Atypical inflammation in the central nervous system in prion disease. Curr Opin Neurol 2002;15:349-54
39. Davies S, Nicholson T, Laura M, et al. Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis. J Neuropathol Exp Neurol 2005;64:371-77
40. Trieb K, Ransmayr G, Sgonc R, et al. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging 1996;17:541-47
41. Giubilei F, Antonini G, Montesperelli C, et al. T cell response to amyloid-beta and to mitochondrial antigens in Alzheimer's disease. Dement Geriatr Cogn Disord 2003;16:35-38
42. Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid b protein in older humans and patients with Alzheimer disease. J Clin Invest 2003;112:415-22
43. Baril L, Nicolas L, Croisile B, et al. Immune response to A beta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett 2004;355:226-30
44. Cashman NR, Loertscher R, Nalbantoglu J, et al. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell 1990;61:185-92
45. Mattei V, Garofalo T, Misasi R, et al. Prion protein is a component of the multimolecular signaling complex involved in T cell activation. FEBS Lett 2004;560:14-18
46. Polymenidou M, Heppner FL, Pellicioli EC, et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci U S A 2004;101:14670-76
47. Holada K, Vostal JG. Different levels of prion protein (PrPc) expression on hamster, mouse and human blood cells. Br J Haematol 2000;110:472-80
48. Heppner FL, Aguzzi A. Recent developments in prion immunotherapy. Curr Opin Immunol 2004;16:594-98
49. Gregoire S, Bergot AS, Feraudet C, et al. The murine B cell repertoire is severely selected against endogenous cellular prion protein. J Immunol 2005;175:6443-49
50. Souan L, Margalit R, Brenner O, et al. Self prion protein peptides are immunogenic in Lewis rats. J Autoimmun 2001;17:303-10
51. Tenzer S, Stoltze L, Schonfisch B, et al. Quantitative analysis of prion-protein degradation by constitutive and immuno-20s proteasomes indicates differences correlated with disease susceptibility. J Immunol 2004;172:1083-91
52. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: From basic science to medicine. Arthritis Res 2002;4 (suppl 3): S233-42
53. Bacot SM, Lenz P, Frazier-Jessen MR, et al. Activation by prion peptide PrP (106-126) induces a NF-kappaB-driven proinflammatory response in human monocyte-derived dendritic cells. J Leukoc Biol 2003;74:118-25
54. Volkel D, Zimmermann K, Zerr I, et al. C-reactive protein and IL-6: New marker proteins for the diagnosis of CJD in plasma? Transfusion 2001;41:1509-14
55. Rincon M, Anguita J, Nakamura T, et al. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4(+) T cells. J Exp Med 1997;185:461-69
56. Diehl S, Chow CW, Weiss L, et al. Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation. J Exp Med 2002;196:39-49
57. Tal Y, Souan L, Cohen IR, et al. Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J Neurosci Res 2003;71:286-90
58. White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003;422:80-83
59. Cribbs DH, Ghochikyan A, Vasilevko V, et al. Adjuvant-dependent modulation of T(h)1 and T(h)2 responses to immunization with beta-amyloid. Int Immunol 2003;15:505-14
60. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. Nat Rev Neurosci 2002;3:824-28